Your browser doesn't support javascript.
loading
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
Wagner, Verena; Hose, Dirk; Seckinger, Anja; Weiz, Ludmila; Meißner, Tobias; Rème, Thiery; Breitkreutz, Iris; Podar, Klaus; Ho, Anthony D; Goldschmidt, Hartmut; Krämer, Alwin; Klein, Bernard; Raab, Marc S.
Afiliación
  • Wagner V; Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Hose D; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
  • Seckinger A; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Weiz L; Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Meißner T; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Rème T; INSERM U1040, Montpellier, France.
  • Breitkreutz I; Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
  • Podar K; National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
  • Ho AD; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Goldschmidt H; Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
  • Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Klein B; INSERM U1040, Montpellier, France. CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France.
  • Raab MS; Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Oncotarget ; 5(21): 10237-50, 2014 Nov 15.
Article en En | MEDLINE | ID: mdl-25296978
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Naftoquinonas / Proteínas Inhibidoras de la Apoptosis / Respuesta de Proteína Desplegada / Proteína 1 de la Secuencia de Leucemia de Células Mieloides / Imidazoles / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Oncotarget Año: 2014 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Naftoquinonas / Proteínas Inhibidoras de la Apoptosis / Respuesta de Proteína Desplegada / Proteína 1 de la Secuencia de Leucemia de Células Mieloides / Imidazoles / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Oncotarget Año: 2014 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos